Last week brought a flurry of exciting news in the pharmaceutical world. US biotech company Celcuity saw a remarkable 180% increase in its stock value following positive Phase III data for its cancer drug candidate gedatolisib.
Another US drugmaker, Madrigal Pharmaceuticals, struck a licensing deal with China’s CSPC Pharma for the rights to a GLP-1 receptor inhibitor, SYH 2086, enhancing its platform in metabolic dysfunction associated steatohepatitis (MASH). This move was led by Rezdiffra. In a bold move, US President Donald Trump issued an ultimatum to several major pharmaceutical companies, urging them to lower the prices of their drugs in the USA. Additionally, LENZ Therapeutics achieved a significant milestone with the FDA approval of VIZZ, the first aceclidine-based drug for treating presbyopia in adults.
Read more on thepharmaletter.com